For in vivo IL-7 treatment, WT BL/6 mice were chronically exposed to A. fumigatus as described. On days 7, 9, 11 and 14, mice received 1.5 μg of carrier-free recombinant murine IL-7 (R&D Systems) (dose based on refs.33 (link),34 (link)) in a volume of 50 μl intratracheally. Controls received 50 μl of diluent (PBS) intratracheally. For in vivo anti-IL-7R (CD127) blockade, WT BL/6 mice were chronically exposed to A. fumigatus as described. On days 7, 9, 11 and 14, mice received 0.5 mg of InVivoMAb rat anti-mouse IL-7Rα/CD127 (Catalog #BE0065, Bio X Cell, West Lebanon, NH) in a volume of 0.2 ml intraperitoneally. Controls received 0.5 mg of InVivoMAb Rat IgG2a Isotype control (anti Trinitrophenol; Catalog #BE0089, Bio X Cell).
Invivomab rat igg2a isotype control anti trinitrophenol
Manufactured by BioXCell
InVivoMAb Rat IgG2a Isotype control (anti Trinitrophenol) is a laboratory reagent used as a control in immunological experiments. It is a rat immunoglobulin G2a (IgG2a) monoclonal antibody that binds to the hapten Trinitrophenol. This reagent is intended to be used as an isotype control in experiments involving rat IgG2a antibodies.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using invivomab rat igg2a isotype control anti trinitrophenol
1
In vivo IL-7 treatment and anti-IL-7R blockade in Aspergillus fumigatus infection
2
CD8+ T Cell Depletion and EZM8266 Treatment
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
On days −3, −2, and −1, mice received a daily i.p. injection of either 500 μg anti-CD8a antibody (BioXCell, Cat. no. BE0004-1; RRID:AB_1107671) or 500 μg InVivoMAb rat IgG2a isotype control, anti-trinitrophenol (BioXCell, Cat. #BE0079). InVivoPure pH 6.5 dilution buffer (BioXCell, Cat. #IP0065) was used as a vehicle for both antibodies. On day 0, CD8 T cell depletion was validated via flow cytometry (Figure S5A –B ), and mice within each antibody group were randomized into four treatment groups based on IVIS total flux: IgG2a + Vehicle control (n = 9), Anti-CD8a antibody (n = 10), 150 mg/kg EZM8266 (n = 9), and Anti-CD8a + EZM8266 (n = 10). EZM8266 was administered daily via oral gavage, and 250 μg anti-CD8a antibody was administered via i.p. injection twice per week starting on day 1.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!